References
- 1
Bateson A.
Further potential of the GABA receptor in the treatment of insomnia.
Sleep Medicine.
2007;
7
3-9
- 2
Montgomery SA.
Pregabalin for the treatment of generalized anxiety disorder.
Expert Opin Pharmacother.
2006;
7
2139-2154
- 3
Rupprecht R, Eser D, Zwanzger P, Möller HJ.
GABA-A receptors as targets for novel anxiolytic drugs.
World J Biol Psychiatry.
2006;
7
231-237
- 4
Taylor CP, Angelotti T, Fauman E.
Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta
(alpha2-delta) subunit as a target for antiepileptic drug discovery.
Epilepsy Res.
2007;
73
137-150
- 5
Victorri-Vigneau C, Guerlais M, Jolliet P.
Abuse, dependency and withdrawal with gabapentin: a first case report.
Pharmacopsychiatry.
2007;
40
43-44
- 6
Zullino DF, Khazaal Y, Hattenschwiler J, Borgeat F, Besson J.
Anticonvulsant drugs in the treatment of substance withdrawal.
Drugs Today (Barc).
2004;
40
603-619
Correspondence
Dr. med. T. Biermann
Friedrich-Alexander-University of Erlangen-Nuremberg
Department of Psychiatry and Psychotherapy
Schwabachanlage 6-10
91054 Erlangen
Germany
Phone: +49/9131/853 45 97
Fax: +49/9131/853 41 05
Email: teresa.biermann@uk-erlangen.de
